期刊
VACCINE
卷 28, 期 3, 页码 707-713出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.10.080
关键词
Mucosal vaccines; Nasal vaccination; Oral vaccination; Pseudomonas vaccine; OprF-OprI; CVD908; Ty21a
资金
- German Research Council (Deutsche Forschungsgemeinschaft, DFG) [SP170/11-1, SFB621-A9]
- German Cystic Fibrosis Foundation
- Mukoviszidose e.V., Bonn
- Appenrodt-Foundation, Hanover, Germany
Vaccination against Pseudomonas aeruginosa is a desirable, yet challenging strategy for prevention of airway infection in patients with cystic fibrosis. We compared the formation of antibodies in lower airways induced by systemic and mucosal vaccination strategies. We immunised 48 volunteers in six vaccination groups with either a systemic, a nasal, or four newly constructed oral live vaccines based on attenuated live Salmonella (strains CVD908 and Ty21a). followed by a systemic booster vaccination All vaccines were based on a recombinant fusion protein of the highly conserved P aeruginosa outer membrane proteins OprF and OprI as antigen. While systemic and mucosal vaccines induced a comparable rise of serum antibody titers, a significant rise of IgA and IgG antibodies in the lower airways was noted only after nasal and oral vaccinations. We conclude that nasal and oral OprF-OprI vaccines are promising candidates for development of antipseudomonal immunisation through inducing a specific antibody response in the lung. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据